Zacks Investment Research downgraded shares of vTv Therapeutics Inc. (NASDAQ:VTVT) from a hold rating to a sell rating in a research note released on Wednesday.

According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “

VTVT has been the topic of a number of other research reports. HC Wainwright began coverage on vTv Therapeutics in a research report on Monday, September 26th. They issued a buy rating and a $13.00 price target on the stock. Canaccord Genuity reaffirmed a buy rating and issued a $15.00 price objective on shares of vTv Therapeutics in a research note on Friday, August 19th.

Shares of vTv Therapeutics (NASDAQ:VTVT) traded down 0.29% during mid-day trading on Wednesday, hitting $6.96. The stock had a trading volume of 1,309 shares. The firm’s market capitalization is $67.44 million. The stock’s 50-day moving average is $6.50 and its 200-day moving average is $5.92. vTv Therapeutics has a 1-year low of $4.84 and a 1-year high of $8.22.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Tuesday, August 16th. The company reported ($0.47) EPS for the quarter. Equities analysts expect that vTv Therapeutics will post ($1.61) earnings per share for the current year.

Several institutional investors have recently bought and sold shares of VTVT. BlackRock Investment Management LLC raised its position in vTv Therapeutics by 25.3% in the second quarter. BlackRock Investment Management LLC now owns 27,758 shares of the company’s stock worth $161,000 after buying an additional 5,596 shares in the last quarter. Geode Capital Management LLC raised its position in vTv Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 34,884 shares of the company’s stock worth $180,000 after buying an additional 822 shares in the last quarter. Kennedy Capital Management Inc. bought a new position in vTv Therapeutics during the first quarter worth approximately $282,000. State Street Corp raised its position in vTv Therapeutics by 10.9% in the first quarter. State Street Corp now owns 61,239 shares of the company’s stock worth $316,000 after buying an additional 6,000 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its position in vTv Therapeutics by 23.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 96,439 shares of the company’s stock worth $559,000 after buying an additional 18,112 shares in the last quarter. 12.84% of the stock is currently owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

5 Day Chart for NASDAQ:VTVT

Receive News & Stock Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related stocks with our FREE daily email newsletter.